Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given a consensus recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $34.00.

Several research analysts have recently issued reports on RCUS shares. Barclays lifted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price for the company. Finally, HC Wainwright reiterated a “neutral” rating and issued a $20.00 price objective on shares of Arcus Biosciences in a report on Wednesday, November 6th.

Arcus Biosciences Trading Down 0.5 %

NYSE RCUS opened at $15.83 on Friday. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -5.03 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences has a 12 month low of $13.52 and a 12 month high of $20.31. The firm’s fifty day moving average price is $16.19 and its 200 day moving average price is $16.06.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.06. The business had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s quarterly revenue was up 50.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.94) earnings per share. On average, sell-side analysts expect that Arcus Biosciences will post -3.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Arcus Biosciences by 6.9% in the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock valued at $68,309,000 after acquiring an additional 286,766 shares during the period. Point72 Asset Management L.P. grew its holdings in Arcus Biosciences by 32.9% during the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock worth $37,263,000 after acquiring an additional 603,222 shares during the period. Parkman Healthcare Partners LLC grew its stake in shares of Arcus Biosciences by 146.9% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock worth $15,684,000 after purchasing an additional 610,219 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Arcus Biosciences by 25.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock worth $14,236,000 after acquiring an additional 186,750 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Arcus Biosciences by 11.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after buying an additional 59,536 shares during the period. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.